Chapman-Fredricks Jennifer, Sandoval-Sus Jose, Vega Francisco, Lossos Izidore S
Division of Hematopathology, Department of Pathology, University of Miami, Miami, FL.
Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.
Ann Diagn Pathol. 2014 Aug;18(4):214-9. doi: 10.1016/j.anndiagpath.2014.03.006. Epub 2014 Apr 13.
Leukemic, non-nodal mantle cell lymphoma (MCL) is a relatively indolent disease characterized by asymptomatic leukemic presentation, non-nodal disease distribution, and slow disease progression, particularly in comparison to that of classic nodal MCL. We studied 3 cases of leukemic, non-nodal MCL in which TP53, ATM, and/or 13q14 deletions were identified. All three patients had disease progression leading to treatment requirements in two of the patients at 5 and 18 months after initial diagnosis. The third patient also clinically progressed 25 months after initial diagnosis but was lost to follow up despite recommendation for initiation of therapy. We present these cases as potential evidence that while leukemic non-nodal MCL is typically an indolent disease compared to classically defined mantle cell lymphoma, cytogenetic heterogeneity exists and cases with TP53, ATM, and/or 13q14 deletions may have a relatively aggressive clinical course.
白血病性非淋巴结套细胞淋巴瘤(MCL)是一种相对惰性的疾病,其特征为无症状的白血病表现、非淋巴结疾病分布以及疾病进展缓慢,尤其是与经典淋巴结MCL相比。我们研究了3例白血病性非淋巴结MCL病例,其中发现了TP53、ATM和/或13q14缺失。所有3例患者均出现疾病进展,其中2例患者在初诊后5个月和18个月时需要接受治疗。第3例患者在初诊后25个月也出现临床进展,但尽管建议开始治疗,仍失访。我们展示这些病例作为潜在证据,表明虽然白血病性非淋巴结MCL与经典定义的套细胞淋巴瘤相比通常是一种惰性疾病,但存在细胞遗传学异质性,具有TP53、ATM和/或13q14缺失的病例可能具有相对侵袭性的临床病程。